Screener
Ligand Pharmaceuticals LGND Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Royalties | 48,032 | 36,397 | 90,990 | 63,886 |
| Captisol | 7,978 | 8,287 | 16,632 | 21,747 |
| Contract revenue and income | 7,683 | 2,943 | 7,793 | 7,327 |
| Total revenues and income | 63,693 | 47,627 | 115,415 | 92,960 |
| Operating costs and expenses: | ||||
| Cost of Captisol | 3,214 | 2,907 | 6,487 | 7,756 |
| Amortization of intangibles | 8,097 | 8,258 | 16,194 | 16,515 |
| Research and development | 14,668 | 6,567 | 16,816 | 56,652 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's total revenue?
- Ligand Pharmaceuticals (LGND) reported total revenue of $63.69M in Q2 2026.
- How has Ligand Pharmaceuticals's total revenue changed year-over-year?
- Ligand Pharmaceuticals's total revenue increased by 33.7% year-over-year, from $47.63M to $63.69M.
- What is the long-term trend for Ligand Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's total revenue has grown at a 2.6% compound annual growth rate (CAGR), from $241.54M to $268.09M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Ligand Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude